CAPRICOR THERAPEUTICS, INC. (CAPR)
$9.59-$0.47 (-4.65%) Today
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 6 | 50,000 | $1.52M |
| Option exercise | 12 | 100,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
26 Form 4 filings on record, the earliest from Dec 4, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Karen Krasney - Officer | Option exercise | Common Stock | 24,100 | $3.18 | $77K | |
| Karen Krasney - Officer | Open-market sale | Common Stock | 24,100 | $30.38 | $732K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 24,100 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 24,100 | $3.18 | $77K | |
| Anthony Bergmann - Officer | Open-market sale | Common Stock | 24,100 | $30.38 | $732K | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 24,100 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Common Stock | 500 | $3.18 | $2K | |
| Karen Krasney - Officer | Open-market sale | Common Stock | 500 | $30.00 | $15K | |
| Karen Krasney - Officer | Option exercise | Common Stock | 400 | $3.18 | $1K | |
| Karen Krasney - Officer | Open-market sale | Common Stock | 400 | $30.00 | $12K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 500 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 400 | $0.00 | - | |
| Anthony Bergmann - Officer | Open-market sale | Common Stock | 500 | $30.00 | $15K | |
| Anthony Bergmann - Officer | Open-market sale | Common Stock | 400 | $30.00 | $12K | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 500 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 400 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 500 | $3.18 | $2K | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 400 | $3.18 | $1K | |
| Michael T. Maurer - Officer | Grant or award | Stock Option (Right to Buy) | 80,000 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 3,000 | $1.39 | $4K | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Frank Litvack | Option exercise | Common Stock | 3,937 | $1.39 | $5K | |
| Frank Litvack | Option exercise | Stock Option (Right to Buy) | 3,937 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Common Stock | 25,000 | $3.18 | $80K | |
| Karen Krasney - Officer | Open-market sale | Common Stock | 25,000 | $31.70 | $793K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 25,000 | $3.18 | $80K | |
| Anthony Bergmann - Officer | Open-market sale | Common Stock | 25,000 | $31.70 | $793K | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Karimah Es Sabar | Option exercise | Common Stock | 7,529 | $3.18 | $24K | |
| Karimah Es Sabar | Open-market sale | Common Stock | 7,529 | $32.00 | $241K | |
| Karimah Es Sabar | Option exercise | Stock Option (Right to Buy) | 7,529 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Common Stock | 693 | $1.39 | $963 | |
| Karen Krasney - Officer | Option exercise | Common Stock | 21,488 | $3.74 | $80K | |
| Karen Krasney - Officer | Option exercise | Common Stock | 2,819 | $3.18 | $9K | |
| Karen Krasney - Officer | Open-market sale | Common Stock | 25,000 | $30.12 | $753K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 693 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 21,488 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 2,819 | $0.00 | - | |
| Karimah Es Sabar | Option exercise | Common Stock | 61,265 | $4.86 | $298K | |
| Karimah Es Sabar | Option exercise | Common Stock | 53,735 | $4.86 | $261K | |
| Karimah Es Sabar | Open-market sale | Common Stock | 61,265 | $30.17 | $1.85M | |
| Karimah Es Sabar | Open-market sale | Common Stock | 53,735 | $31.03 | $1.67M | |
| Karimah Es Sabar | Option exercise | Stock Option (Right to Buy) | 61,265 | $0.00 | - | |
| Karimah Es Sabar | Option exercise | Stock Option (Right to Buy) | 53,735 | $0.00 | - | |
| Anthony Bergmann - Officer | Option exercise | Common Stock | 25,000 | $3.18 | $80K | |
| Anthony Bergmann - Officer | Open-market sale | Common Stock | 25,000 | $30.13 | $753K | |
| Anthony Bergmann - Officer | Option exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Common Stock | 2,500 | $1.39 | $3K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 2,500 | $0.00 | - | |
| Linda Marban - Officer | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Linda Marban - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Linda Marban - Officer | Grant or award | Restricted Stock Units | 7,500 | $0.00 | - | |
| Anthony Bergmann - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Anthony Bergmann - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | $0.00 | - | |
| Anthony Bergmann - Officer | Grant or award | Restricted Stock Units | 2,500 | $0.00 | - | |
| Karen Krasney - Officer | Grant or award | Stock Option (Right to Buy) | 22,500 | $0.00 | - | |
| Karen Krasney - Officer | Grant or award | Stock Option (Right to Buy) | 22,500 | $0.00 | - | |
| Paul Gisbert Auwaerter | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| Paul Gisbert Auwaerter | Grant or award | Stock Option (Right to Buy) | 1,360 | $0.00 | - | |
| Paul Gisbert Auwaerter | Grant or award | Stock Option (Right to Buy) | 5,420 | $0.00 | - | |
| Mike Kelliher | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| Philip J. Gotwals | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| Karimah Es Sabar | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| David B. Musket | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| George W. Dunbar Jr. | Grant or award | Stock Option (Right to Buy) | 15,500 | $0.00 | - | |
| Frank Litvack | Grant or award | Stock Option (Right to Buy) | 50,000 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Common Stock | 8,000 | $1.39 | $11K | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 3,000 | $0.00 | - | |
| Karen Krasney - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| Frank Litvack | Option exercise | Common Stock | 20,391 | $1.10 | $22K | |
| Frank Litvack | Gift | Warrants (Right to Buy) | 20,391 | $0.00 | - | |
| Frank Litvack | Gift | Warrants (Right to Buy) | 20,391 | $0.00 | - | |
| Frank Litvack | Option exercise | Warrants (Right to Buy) | 20,391 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
CAPRICOR THERAPEUTICS, INC. (CAPR) had 4 insider filings in the last 90 days, with the most recent on 2026-06-30. The full record for CAPR runs to 26 Form 4 filings, the earliest from 2024-12-04. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CAPR were filed in the last 90 days.
6 insider sales of CAPR were filed in the last 90 days, totaling $1.52M.
This page tracks CAPR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CAPR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
